CareDx (NASDAQ: CDNA) reported Q4 EPS of $0.09, $0.07 better than the analyst estimate of $0.02. Revenue for the quarter came in at $58.6 million versus the consensus estimate of $55.51 million.

"Our record fourth quarter result was the culmination of an extraordinary year for CareDx," said Reg Seeto, President and Chief Executive Officer of CareDx. "2020 was transformational for CareDx, because we extended our leadership position in transplant centers through RemoTraC, implemented and validated the next wave of innovation through our multi-modality platforms, HeartCare and KidneyCare, and accelerated the direct to patient journey through AlloCare. We look forward to 2021 and beyond as we invest in advancing our robust pipeline and continue our mission to serve transplant patients and improve outcomes."

For earnings history and earnings-related data on CareDx (CDNA) click here.